MoDETM Degraders

Biohaven’s lead MoDE degrader, BHV-1300, is designed to remove pathogenic IgG antibodies that drive disease, offering a targeted approach to addressing the root cause of Graves’ disease.

Hear Emma share her story about living with Graves’ disease and the impact to her daily life.

Injector
MoDE Degraders are administered via subcutaneous or IV injection
bind to circulating disease-causing proteins
and deliver them to ASGPRs on hepatocytes
for internalization and degradation

HEPATOCYTE

Researching the safe and effective treatment of BHV-1300 for patients with Graves’

Drug:

BHV-1300

Ages:

18-65

Phase:

1